Phase II randomized study of first-line therapy comprising bevacizumab and irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) versus bevacizumab and irinotecan hydrochloride and capecitabine (XELIRI) in patients with unresectable metastatic colorectal cancer [ACCORD].

Trial Profile

Phase II randomized study of first-line therapy comprising bevacizumab and irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) versus bevacizumab and irinotecan hydrochloride and capecitabine (XELIRI) in patients with unresectable metastatic colorectal cancer [ACCORD].

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2013

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms ACCORD
  • Most Recent Events

    • 27 Sep 2011 Follow-up results presented at the 2011 European Multidisciplinary Cancer Congress.
    • 12 Oct 2009 Preliminary results from the first six months of follow-up were presented at the 15th European Cancer Conference and the 34th Congress of the European Society for Medical Oncology.
    • 22 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top